The dietary compound luteolin inhibits pancreatic cancer growth by targeting BCL-2
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The dietary compound luteolin inhibits pancreatic cancer growth by targeting BCL-2
Authors
Keywords
-
Journal
Food & Function
Volume 9, Issue 5, Pages 3018-3027
Publisher
Royal Society of Chemistry (RSC)
Online
2018-04-19
DOI
10.1039/c8fo00033f
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
- (2017) Avi Ashkenazi et al. NATURE REVIEWS DRUG DISCOVERY
- Farnesyl phenolic enantiomers as natural MTH1 inhibitors from Ganoderma sinense
- (2017) Ya Gao et al. Oncotarget
- Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane
- (2016) Katelyn L. O'Neill et al. GENES & DEVELOPMENT
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase
- (2016) Xiaoyu Zeng et al. Oncotarget
- Novel small molecule 11β-HSD1 inhibitor from the endophytic fungus Penicillium commune
- (2016) Weiguang Sun et al. Scientific Reports
- The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers
- (2016) Abdulraheem Alshareef et al. Scientific Reports
- The BCL-2 protein family, BH3-mimetics and cancer therapy
- (2015) A R D Delbridge et al. CELL DEATH AND DIFFERENTIATION
- An interconnected hierarchical model of cell death regulation by the BCL-2 family
- (2015) Hui-Chen Chen et al. NATURE CELL BIOLOGY
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax and show no preference for Bak versus Bax
- (2015) C Hockings et al. Cell Death & Disease
- Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer
- (2014) A Zeuner et al. CELL DEATH AND DIFFERENTIATION
- Targeting BCL2 for the Treatment of Lymphoid Malignancies
- (2014) Mary Ann Anderson et al. SEMINARS IN HEMATOLOGY
- Many players in BCL-2 family affairs
- (2014) Tudor Moldoveanu et al. TRENDS IN BIOCHEMICAL SCIENCES
- miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death
- (2013) Zhiyu Chen et al. Molecular Cancer
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
- (2013) D. M. Molina et al. SCIENCE
- BCL-2 Inhibitor Yields High Response in CLL and SLL
- (2013) Cancer Discovery
- Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists
- (2012) Heidi L. Perez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models
- (2011) Nguyen Tan et al. CLINICAL CANCER RESEARCH
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- BH3-only proteins: Orchestrators of apoptosis
- (2010) Aisha Shamas-Din et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX
- (2010) Bonsu Ku et al. CELL RESEARCH
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- The BCL-2 Family Reunion
- (2010) Jerry E. Chipuk et al. MOLECULAR CELL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now